| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03170193 | AMG 529 First in Human Study | PHASE1 | COMPLETED | 48 | — | — | May 15, 2017 | Nov 17, 2017 | Jul 5, 2019 | 1 | United States |
Determination of the severity of adverse events was according to the following: grade 1 = mild (eg, asymptomatic or mild symptoms); grade 2 = moderate (eg, minimal intervention indicated or interferes with activity); grade 3 = severe (eg, medically significant but not immediately life-threatening, prevents daily activity, or requires treatment); grade 4 = life-threatening (ie, refers to an event in which the participant was, in the view of the investigator, at risk of death at the time of the event); and grade 5 = fatal. A serious adverse event was defined as an adverse event that met at least 1 of the following criteria: * fatal * life threatening * required in patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event.
| Arm | Type | Description |
|---|---|---|
| AMG 529 | EXPERIMENTAL | Participants received a single dose of AMG 529 at ascending dose levels by either subcutaneous or intravenous injection. |
| Placebo | PLACEBO_COMPARATOR | Participants received a single dose of placebo matching to AMG 529 by either subcutaneous or intravenous injection. |
| Name | Type | Description |
|---|---|---|
| AMG 529 | DRUG | Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection |
| Placebo | DRUG | Single doses of matching placebo by SC or IV injection |
Inclusion Criteria: 1. Healthy men and women ≥ 18 to ≤ 55 years old with no history or evidence of clinically relevant medical disorders 2. Body mass index (BMI) between 18 and 32 kg/m², inclusive, at screening 3. Women must be of non-reproductive potential as defined in protocol 4. Other inclusion...